Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Manon, van der Lee"'
Autor:
Michiel, van der Flier, Gwenda, Verweel, Linda C, van der Knaap, Petronette, van Jaarsveld, Gert-Jan, Driessen, Manon, van der Lee, Nico G, Hartwig, David M, Burger
Publikováno v:
Antiviral therapy. 13(8)
Recently, a new tablet formulation of the widely used HIV protease inhibitor lopinavir/ritonavir was licensed. Here, we present a pilot study of the pharmacokinetics of the new adult tablet formulation taken once daily in children.Lopinavir pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5261f5fc7300e4d65aefd55fd0faa86f
https://pubmed.ncbi.nlm.nih.gov/19195335
https://pubmed.ncbi.nlm.nih.gov/19195335
Autor:
Manon, van der Lee, Raaj, Sankatsing, Emile, Schippers, Martin, Vogel, Gerd, Fätkenheuer, Andre, van der Ven, Frank, Kroon, Jürgen, Rockstroh, Christoph, Wyen, Anselm, Bäumer, Eric, de Groot, Peter, Koopmans, Erik, Stroes, Peter, Reiss, David, Burger
Publikováno v:
Antiviral therapy. 12(7)
Lopinavir/ritonavir-containing antiretroviral therapy can cause hyperlipidaemia. However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin undergoes minimal metabolism by CYP450, so no CYP450-based interaction with lopinav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85bcea204c9b20b34cf0b07d9333ca20
https://pubmed.ncbi.nlm.nih.gov/18018771
https://pubmed.ncbi.nlm.nih.gov/18018771
Publikováno v:
Antiviral therapy. 11(4)
Lopinavir is an HIV protease inhibitor that is co-formulated with ritonavir. The approved paediatric dose is 230/57.5 mg/m2 twice daily. Once-daily dosing may offer an advantage to adherence. We studied the pharmacokinetics of lopinavir/ritonavir in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c9ad4fa1e58a389356071b574c4e6860
https://pubmed.ncbi.nlm.nih.gov/16856617
https://pubmed.ncbi.nlm.nih.gov/16856617
Autor:
Timo A. Lakka, Manon van der Lee, Sari Voutilainen, Jukka T. Salonen, Meri Vanharanta, Herman Adlercreutz
Publikováno v:
Scopus-Elsevier
Summary Background The lignan enterolactone, produced by the intestinal microflora from dietary precursors, has been implicated in protection against cancer. We investigated the association of serum enterolactone concentration with the risk of acute
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e318cf1498c7d6d587d087beb44952fa
https://pubmed.ncbi.nlm.nih.gov/10821384
https://pubmed.ncbi.nlm.nih.gov/10821384